Belzutifan is used for certain forms of kidney cancer and tumours associated with Von Hippel-Lindau (VHL) syndrome. For eligible patients, starting treatment promptly is essential to ensure continuity of care.
In Belgium, a situation occurred where a patient urgently needed access to this treatment. As the medicine was not reimbursed, the patient had to cover the full cost personally. This made not only fast delivery, but also an affordable solution essential.
The patient could not postpone the treatment, but also needed a supplier that could provide the medicine quickly and at the most favourable possible price.
Finding the right supplier was therefore crucial to start the therapy without unnecessary delays.
Orphamed was contacted to investigate the availability of Belzutifan. By analysing different international suppliers, the most suitable solution was identified quickly.
After comparing several distributors, Orphamed selected the party that could deliver the medicine the fastest at the most competitive price. The entire process, from sourcing to delivery, was carefully coordinated to ensure that the patient could access the treatment as quickly as possible.
Thanks to Orphamed’s fast sourcing and competitive pricing, the patient was able to start the necessary treatment without delay, despite the lack of reimbursement.
This case shows how a strong international network, fast decision-making and an efficient approach contribute to timely access to essential medicines, even when financing presents an additional challenge.
Do you urgently need access to a specific medicine or are you looking for a reliable partner for international sourcing? Contact us via orders@orphamed.nl
At Orphamed, we continue to invest in growth, quality and reliability. With the opening of our…
At Orphamed, we continue to invest in growth, quality and reliability. With the opening of our…
At Orphamed, we continue to invest in growth, quality and reliability. With the opening of our…
